Supplementary Material for: Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)
Robert M.
Jarlier M.
Gourgou S.
Desseigne F.
Ychou M.
Bouché O.
Juzyna B.
Conroy T.
Bennouna J.
10.6084/m9.figshare.5472751.v1
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Retrospective_Analysis_of_CA19-9_Decrease_in_Patients_with_Metastatic_Pancreatic_Carcinoma_Treated_with_FOLFIRINOX_or_Gemcitabine_in_a_Randomized_Phase_III_Study_ACCORD11_PRODIGE4_/5472751
<p><b><i>Objectives:</i></b> Carbohydrate antigen 19-9 (CA19-9) is a
sensitive and specific serum marker in pancreatic cancer. Our
retrospective analysis aims to evaluate CA19-9 decrease in patients with
metastatic pancreatic cancer treated in ACCORD11/PRODIGE4 (FOLFIRINOX
vs. gemcitabine). <b><i>Methods:</i></b> A total of 342 patients were
treated. CA19-9 was measured at 8 weeks (±2) in 160 patients from a
total of 282 with abnormal CA19-9 values at baseline (gemcitabine arm, <i>n</i> = 75; FOLFIRINOX arm, <i>n</i>
= 85). In the present study, 8-week CA19-9 decrease or greater CA19-9
decrease according to the 20 and 90% thresholds were analyzed.
Progression-free survival (PFS) and overall survival (OS) were estimated
in each subgroup. <b><i>Results:</i></b> In the FOLFIRINOX arm,
patients with an 8-week CA19-9 decrease or greater CA19-9 decrease ≥20%
showed improved median OS, PFS, and objective response rate. In the
overall study population, median OS and PFS were significantly improved
in patients with an 8-week CA19-9 decrease ≥20% (vs. <20%). The
8-week CA19-9 decrease was predictive of PFS (interaction test
significant according to treatment arm; <i>p</i> = 0.006). <b><i>Conclusion:</i></b>
An 8-week CA19-9 decrease ≥20% is a prognostic factor for OS and PFS.
The 8-week CA19-9 decrease (20% threshold) is predictive of PFS. It
could help to evaluate the efficacy of FOLFIRINOX and gemcitabine
regimens.</p>
2017-10-05 12:29:17
Metastatic pancreatic cancer
FOLFIRINOX
ca19-9
Biomarkers